A Single-Arm, Open-Label, Pilot Study of JAK Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Phase of Trial: Phase I
Latest Information Update: 16 Sep 2019
Price : $35 *
At a glance
- Drugs Itacitinib (Primary)
- Indications Cytokine release syndrome; Graft-versus-host disease
- Focus Therapeutic Use
- 11 Sep 2019 Status changed from not yet recruiting to recruiting.
- 29 Aug 2019 Planned End Date changed from 31 Jul 2022 to 30 Jun 2022.
- 29 Aug 2019 Planned primary completion date changed from 30 Apr 2022 to 30 Jun 2022.